Advanced ADC Design Shows Marked Increase in Therapeutic Index for Powerful DNA-targeting Payloads

Time: 11:30 am
day: day 1 track 2 am


• Tumor-selective linker and
prodrug technology leads to
improved toxicity profiles and
therapeutic margins for high
potency ADC payloads
• Case study: Moving IKS03, a
best-in-class CD19-targeting
ADC with tumor-selective
technology, toward the clinic